Multi-particulates offer precise control over drug release profiles, making them ideal for modified release forms. We specialize in manufacturing pellets with various release profiles (immediate, delayed, controlled, sustained, targeted, etc.), reducing dosage frequency, and minimizing side effects for enhanced patient convenience.

Directly compressible granules are crucial in tablet manufacturing, offering a seamless transition to the final product. With our cutting-edge technology, we specialize in producing these granules, particularly with modified release profiles.Any facility can easily compress them into tablets.Our advanced technological solutions empower PFI customers to address unmet medical needs in their markets.

Masking bitter tastes in oral drugs for special patient populations is a challenge. We’ve mastered taste masking without affecting drug efficacy or shelf life. Our products, including dry powders and orally disintegrating films, enhance patient compliance.

Oral thin films are dissolvable strips placed on the tongue for rapid medication delivery into the bloodstream, providing a convenient alternative to tablets or capsules. We are among the select few companies worldwide equipped with in-house technology for manufacturing oral thin films.

Our patented Thinoral® technology produces instantly wettable, rapidly dissolving films that are non-sticky, non-tacky, and non-curving. With the capability to load up to 50-60 mg of active drug, this technology ensures uniform thinness, offering a large surface area for dissolution. It effectively addresses solubility issues associated with poorly soluble drugs and is suitable for delivering thermolabile medications.

MucoStrip® Technology offers a unique dosage form that is not swallowed but placed on the tongue, requiring no water for administration.

Sublingual Technology involves administering drugs under the tongue for rapid absorption.

Bilayer Oral Thin Film Technology reduces pill burden by enabling the administration of two or more Active Pharmaceutical Ingredients (APIs) in a single fixed dose combination (FDC).

Combining Nanotechnology and Thin Oral® Technology enhances drug bioavailability, especially for poorly soluble drugs with crystalline Active Pharmaceutical Ingredients (APIs). This innovative approach tackles solubility challenges, resulting in improved drug delivery and therapeutic outcomes.

Our technology revolutionizes pharmaceutical processes, ensuring precise drug content uniformity and optimizing yield, especially for controlled substances like opioids. It accommodates combination drug delivery, providing a comprehensive solution for precision and efficiency in manufacturing potent pharmaceuticals.

Our technology offers a non-invasive oral spray alternative to injectables, focusing on delivering large molecules like peptides and hormonal therapies. It has been validated for effectiveness through proof-of-concept completion. Built on a proprietary, patented process, it holds patents in key regions (US, Canada, India, and Brazil), ensuring exclusivity and protection.

Used for the solubilisation of oil-soluble drugs, liquids in the oil phase, and subsequently, micro-emulsifying with an aqueous phase containing polymers to coat the substrate.

Used for heat sensitive material that either loses its potency or transforms into another form for processing at normal temperatures.

It is used for release of drugs in pseudo zero kinetics and is also an alternative to OROS® technology.

Used for the release of drugs through pores into an aqueous medium